Trial Profile
A Prospective Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms OPTIMIZATION
- Sponsors Sanofi
- 16 Jun 2020 Results of post hoc analysis exploring the predictive effect of baseline fasting C-peptide (FCP) on hypoglycemia risk, HbA1c reduction, and treatment satisfaction in Chinese T2DM individuals switching from premixed to basal insulin presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 12 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2009 Actual patient number (313) added as reported by ClinicalTrials.gov.